Source comparison
Sexual Performance Peptides 2026 Update: Peptide Comparison
Before selecting a peptide, researchers need to understand how each compound differs mechanistically and what those differences mean for study design. PT-141 (Bremelanotide) Melanocortin receptor agonist. Hypothalamic dopamine/oxytocin release MC3R, MC4R 0.75–
This comparison does not assign a generated winner or score.
- Before selecting a peptide, researchers need to understand how each compound differs mechanistically and what those differences mean for study design.
- PT-141 (Bremelanotide)
- Melanocortin receptor agonist. Hypothalamic dopamine/oxytocin release
- MC3R, MC4R
- 0.75–1.75mg subcutaneous
- 45–90 minutes
- Phase 3 FDA-approved for HSDD in women
- Most selective for sexual arousal without peripheral side effects. Gold standard for central-acting compounds
- Kisspeptin-10
- GPR54 receptor agonist. Stimulates GnRH, LH, and testosterone secretion
- GPR54
- 1.0–4.0 nmol/kg IV
- 60–120 minutes
- Phase 2 trials for hypogonadism
- Addresses hormonal insufficiency, not arousal pathways. Best for low-testosterone-related dysfunction
- Melanotan II
- Non-selective melanocortin agonist
- MC1R, MC3R, MC4R
- 0.5–1.0mg subcutaneous
- Observational studies only
- High efficacy for libido but causes hyperpigmentation. Research use only, not clinical
- Oxytocin (intranasal)
- Direct oxytocin receptor binding in limbic system
- OXTR
- 24–48 IU intranasal
- 30–60 minutes
- Phase 2 trials for social bonding, limited sexual function data
- Weak evidence for sexual arousal. Better studied for pair bonding and trust